Key figure in notorious biopharma insider case loses an appeal — broadening scope for future cases
Mathew Martoma will be staying in prison.
A US appeals court ruled today that Martoma’s insider trading conviction three years ago was not tainted by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
